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Abstract
Stem cells can self-renew and produce different cell types, thus providing new strategies to regenerate missing tissues and treat diseases. In the
field of dentistry, adult mesenchymal stem/stromal cells (MSCs) have been identified in several oral and maxillofacial tissues, which suggests that
the oral tissues are a rich source of stem cells, and oral stem and mucosal cells are expected to provide an ideal source for genetically reprogrammed
cells such as induced pluripotent stem (iPS) cells. Furthermore, oral tissues are expected to be not only a source but also a therapeutic target for stem
cells, as stem cell and tissue engineering therapies in dentistry continue to attract increasing clinical interest. Part I of this review outlines various
types of intra- and extra-oral tissue-derived stem cells with regard to clinical availability and applications in dentistry. Additionally, appropriate
sources of stem cells for regenerative dentistry are discussed with regard to differentiation capacity, accessibility and possible immunomodulatory
properties.
# 2012 Japan Prosthodontic Society. Published by Elsevier Ireland. 
Keywords: Dental stem cells; Induced pluripotent stem cells; Mesenchymal stem cells; Regenerative dentistry; Stem cell sources
Contents
1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 152
2. Sources of stem cells in dentistry. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 152
2.1. Adult stem cells . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 153
2.1.1. Introduction to MSCs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 153
2.1.2. Bone marrow-derived MSCs (BMSCs) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 153
2.1.3. Dental tissue-derived stem cells . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 154
2.1.4. Oral mucosa-derived stem cells . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 156
2.1.5. Periosteum-derived stem/progenitor cells . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 156
2.1.6. Salivary gland-derived stem cells . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 157
2.1.7. Adipose tissue-derived stem cells (ASCs) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 157
2.2. Pluripotent stem cells . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 158
2.2.1. ES cells. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 158
2.2.2. iPS cells . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 158
3. Suitable stem cells for regenerative dentistry. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 159
3.1. Differentiation capacity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 159
3.2. Accessibility . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 160
3.3. Immunomodulation. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 160
www.elsevier.com/locate/jpor
Available online at www.sciencedirect.com
Journal of Prosthodontic Research 56 (2012) 151–165
Open access under CC BY-NC-ND license.* Corresponding author at: Department of Fixed Prosthodontics, Division of Oromaxillofacial Regeneration, Osaka University Graduate School of Dentistry, 1-8
Yamadaoka, Suita-city, Osaka 565-0871, Japan. Tel.: +81 6 6879 2946; fax: +81 6 6879 2947.
E-mail address: egu@dent.osaka-u.ac.jp (H. Egusa).
1883-1958 # 2012 Japan Prosthodontic Society. Published by Elsevier Ireland. 
http://dx.doi.org/10.1016/j.jpor.2012.06.001
Open access under CC BY-NC-ND license.
4. Conclusions. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 160
Acknowledgements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 160
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 161
H. Egusa et al. / Journal of Prosthodontic Research 56 (2012) 151–1651521. Introduction
Stem cells are immature, unspecialized cells that have the
potential to develop into many different cell lineages via
differentiation. By the conventional definition, these cells can
renew themselves indefinitely through ‘‘self-renewal’’ [1], and
they vary in terms of their location in the body and the type of
cells that they can produce. Recent studies have revealed that
the oral tissues, which are easily accessible for dentists, are a
rich source of stem cells. Given their unique abilities, stem cells
are particularly important for developing innovative technol-
ogies for tissue engineering strategies [2] to regenerate or
replace damaged, diseased or missing tissues and even organs
by in vitro cell manipulation and design of the extracellular
environment.
In dentistry, tissue engineering is also considered to be a new
frontier in the regeneration of missing oral tissues/organs [3,4].
For example, various degrees of alveolar bone resorption occur
after tooth loss/extraction because of periodontal disease,
severe caries, root fractures or accidental trauma [5]. In
addition, the bone resorption in the residual ridge, particularly
in the mandible, continues throughout life in many edentulous
patients [6]. The severe bone resorption in edentulous areas
makes it difficult to restore the missing teeth with dental
implants or denture treatment [7–9] (Fig. 1). Therefore, stem
cell and tissue engineering therapies are expected to provide a
novel capability to regenerate large defects in periodontal
tissues [10] and alveolar bone [11–13], and to ultimately
replace the lost tooth itself [14,15]. The tissues and organs
targeted for such regenerative medicine strategies in dentistry
include the salivary gland [16], tongue [17] and craniofacial
skeletal muscles [18], as well as the condylar cartilage of the
temporomandibular joint [19,20].
Many basic and translational studies with stem cells and
the other key elements of tissue engineering, i.e., bioactiveFig. 1. Alveolar bone resorption. (A) Resorption of the labial bone plate in the m
required to place the dental implant. (B) Some alveolar bone resorption inevitably 
mandible (white arrows) are flattened by bone resorption after tooth loss.
The figure was reproduced with permission from [9].factors and extracellular matrix scaffolds [21,22], have been
conducted in animal models to develop the concept of oral
tissue and organ regeneration for clinical application in
dentistry. In addition, stem cell-based tissue engineering has
already been applied to clinical trials with demonstrated
efficacy in orofacial bone tissue regeneration [11–13] (details
are provided in Part II of this review). Despite these
promising successes, recent findings that various types of
stem cells can be obtained from the oral and maxillofacial
region may lead to confusion regarding the role of stem cells
and regenerative biology in dentistry, particularly with regard
to the optimal type of stem cells for oral tissue and organ
regeneration.
Part I of this review focuses on the types and derivation of
stem cells in dentistry from the viewpoint of clinical
availability. We also discuss appropriate stem cell sources in
dentistry with regard to their differentiation capacity, accessibility
and possible immunomodulatory properties. Part II subsequently
describes the current state of stem cell research and clinical trials
in dentistry.
2. Sources of stem cells in dentistry
There are two primary sources of stem cells: adult stem cells
and embryonic stem (ES) cells. In addition to these stem cells,
which are naturally present in the human body, induced
pluripotent stem (iPS) cells have been recently generated
artificially via genetic manipulation of somatic cells [23,24].
ES cells and iPS cells are collectively referred to as pluripotent
stem cells because they can develop into all types of cells from
all three germinal layers. In contrast, most adult stem cells are
multipotent, i.e., they can only differentiate into a limited
number of cell types. We herein outline the different types of
stem cells under consideration for applications in dentistry in
terms of their clinical availability.axillary anterior occurs after tooth extraction. Alveolar bone augmentation is
occurs after tooth loss (black arrow). The posterior alveolar ridge areas in the
Fig. 2. Sources of adult stem cells in the oral and maxillofacial region. BMSCs: bone marrow-derived MSCs from orofacial bone (see Section 2.1.2); DPSCs: dental
pulp stem cells; SHED: stem cells from human exfoliated deciduous teeth; PDLSCs: periodontal ligament stem cells; DFSCs: dental follicle stem cells; TGPCs: tooth
germ progenitor cells; SCAP: stem cells from the apical papilla (see Section 2.1.3); OESCs: oral epithelial progenitor/stem cells; GMSCs: gingiva-derived MSCs (see
Section 2.1.4), PSCs: periosteum-derived stem cells (see Section 2.1.5); SGSCs: salivary gland-derived stem cells (see Section 2.1.6).
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Adult stem cells are also called somatic stem cells or
postnatal stem cells, and they are found in many tissues and
organs. Although very few of these cells are present in adult
tissues, they undergo self-renewal and differentiation to
maintain healthy tissues and repair injured tissues. Recent
stem cell studies in the dental field have identified many
adult stem cell sources in the oral and maxillofacial region
(Fig. 2). These cells are believed to reside in a specific area of
each tissue, i.e., a ‘‘stem cell niche’’. Many types of adult stem
cells reside in several mesenchymal tissues, and these cells are
collectively referred to as mesenchymal stem cells or multi-
potent mesenchymal stromal cells (MSCs).
2.1.1. Introduction to MSCs
In cell culture, MSCs can be identified and isolated based on
their adherence to tissue-culture-treated plastic [25]. MSCs are
among the most promising adult stem cells for clinical
applications; they were originally found in the bone marrow,
but similar subsets of MSCs have also been isolated from many
other adult tissues, including skin, adipose tissue and various
dental tissues [26–28]. The concept of using adherent
fibroblastic cells isolated from the bone marrow was originally
reported in 1970 by Friedenstein et al. [29]. Those cells were
referred to as colony forming units-fibroblasts, and their
capability to differentiate to various mesenchymal tissues gave
rise to the concept of MSCs [30]. In 1999, Pittenger et al. [31]
characterized human MSCs from the bone marrow of the iliac
crest as multipotent stem cells by demonstrating their isolation,
expansion in culture and directed differentiation to osteogenic,
adipogenic and chondrogenic lineages. Since then, extensive
studies on MSCs have demonstrated their robust multipotency
and even ‘‘stem cell plasticity’’, as exemplified by the capacityof MSCs to differentiate into lineages that are not typical
mesenchymal derivatives [32].
However, the definition of MSCs has been controversial
because the populations of adherent cells isolated from the bone
marrow are not homogeneous, and definitive markers for
distinguishing MSCs have not yet been identified [33]. In 2006,
the International Society for Cellular Therapy (ISCT) proposed
minimal criteria to define human multipotent MSCs; notably,
the ISCT termed MSCs as mesenchymal stromal cells,
regardless of the tissue from which they are isolated [25].
According to the ISCT criteria, MSCs must be adherent to
tissue-culture-treated plastic when maintained in standard
culture conditions. Additionally, MSCs must express CD105,
CD73 and CD90 and lack the expression of CD45, CD34,
CD14 or CD11b, CD79a or CD19 and HLA-DR surface
molecules. Finally, MSCs must be able to differentiate to
osteoblasts, adipocytes and chondroblasts in vitro [34].
Recently, other unique cell surface markers for human MSCs,
such as CD271 [35] and MSC antigen-1 [36], have been
reported. In addition to the use of surface marker analysis, the
selection of MSCs using stable mRNA markers specifically
expressed in the MSCs has been proposed [37,38].
2.1.2. Bone marrow-derived MSCs (BMSCs)
Adult bone marrow contains rare multipotent progenitor
cells that are generally termed BMSCs. Despite their
heterogeneity, BMSCs possess a high replicative capacity
and have the capacity to differentiate into various connective
tissue cell types. In addition, BMSCs robustly form bone in
vivo, which makes them an appropriate stem cell source for
bone regeneration therapy [39].
2.1.2.1. BMSCs from the iliac crest. BMSCs from the iliac
crest have been extensively studied and demonstrated to
Fig. 3. Alveolar bone marrow aspiration and BMSC isolation. (A) Alveolar bone marrow was aspirated from the right maxillary edentulous jaw before the drilling of
the implant sites using a biopsy needle (GC Corporation, Tokyo, Japan). (B) Plastic-adherent BMSCs derived from the bone marrow after 5 days of culture (white
arrows). (C) Expanded alveolar bone-derived BMSCs after 15 days of culture. Bars: 200 mm.
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myogenic or non-mesenchymal neurogenic lineages [31,40–
42]. BMSCs can be easily isolated from the bone marrow of the
iliac crest by physicians, but the bone marrow aspiration
procedure is invasive for the donors. Nonetheless, the stem cells
most commonly used to date for bone regeneration in dental
patients are BMSCs from the iliac crest (details are provided in
Part II of this review). The bone marrow of the iliac crest is the
most documented cell source for MSCs in regenerative
medicine, possibly because it has long been routinely collected
for bone marrow transplantation for leukemia treatment.
Because of their great potential for bone regeneration [39],
BMSCs from the human iliac crest may be applicable to bone
tissue engineering irrespective of the age of the patient [43,44].
However, several reports have demonstrated an age-related
decline in the osteogenic potential of BMSCs isolated from the
human iliac crest and femur [44–46], which suggests that donor
age is an important factor for the clinical efficacy of bone
formation. In addition, the in vitro expansion capability appears
to be limited, as the cells tend to undergo senescence and lose
their multi-differentiation potential with repeated passaging
and culture time [39]. These limitations should be overcome to
successfully utilize BMSCs for bone tissue engineering and
regeneration.
2.1.2.2. BMSCs from orofacial bones. Although the iliac
crest has served as the primary source of BMSCs to date, human
BMSCs can also be isolated from orofacial (maxilla and
mandible) bone marrow aspirates obtained during dental
surgical procedures such as dental implant treatment, wisdom
tooth extraction, extirpation of cysts and orthodontic osteotomy
(Fig. 3). Orofacial bone-derived BMSCs can be obtained not
only from younger patients (6–53 years of age [47]) but also
from relatively aged individuals (57–62 years of age [48]), and
the age of the donor seems to have little effect on the BMSC
gene expression pattern [48].
Clinical observations [49–51] and experimental animal
studies [52–54] have consistently indicated that grafted bone
obtained from the craniofacial area (membranous bone) for
autologous bone grafting at craniofacial sites provides better
results and significantly higher resultant bone volume than bone
harvested from the iliac crest or rib (endochondral bone). These
observations imply that different skeletal donor tissues have
site-specific regenerative properties that may depend upon theBMSC type and BMSC niche present in the graft. Embry-
ologically, the maxilla and mandible bones exclusively
originate from cranial neural crest cells [55], whereas the iliac
crest bone is formed by mesoderm. These differences in
embryological origin may result in functional differences
between orofacial and iliac crest human BMSCs [56,57].
Indeed, it is well documented that the orofacial BMSCs are
phenotypically and functionally different from iliac crest
BMSCs. Igarashi et al. [37] reported that orofacial BMSCs
have a discrete differentiation potential with distinct
expression patterns for several MSC marker genes compared
with tibia-, femur- and ilium-derived BMSCs. Akintoye et al.
[56] demonstrated site-specific properties of orofacial and
iliac BMSCs from the same individuals where higher
proliferation and osteogenic differentiation capacity were
observed for orofacial BMSCs compared with the iliac crest
BMSCs. In addition, the orofacial BMSCs formed more bone in
an in vivo mouse model, whereas the iliac crest BMSCs formed
more compacted bone that included hematopoietic tissue [56].
An animal study also indicated that upon transplantation,
BMSCs from the rat mandible formed larger bone nodules and
more mineralized bone than BMSCs from long bones [58].
Furthermore, the adipogenic potential of orofacial BMSCs is
less than that of iliac BMSCs [47,56], which may decrease
unfavorable fat formation during bone tissue regeneration.
These properties of orofacial BMSCs may provide an
advantage for orofacial bone regeneration. However, the
collectable volume of orofacial bone marrow is less (0.03–
0.5 ml [47,48]) than that of iliac crest bone marrow. Therefore,
a reliable and safe cell expansion protocol should be established
when orofacial BMSCs are used for clinical trials.
2.1.3. Dental tissue-derived stem cells
To date, two types of adult stem cells have been
characterized in dental tissues, i.e., epithelial stem cells and
MSC-like cells. An adult epithelial stem cell niche in teeth was
first demonstrated in 1999 [59] via organ culture of the apical
end of the mouse incisor. The niche is located in the cervical
loop of the tooth apex and possibly contains dental epithelial
stem cells, which can notably differentiate into enamel-
producing ameloblasts. Although the epithelial stem cell niche
is useful for analyses of the fate decision of stem cells in tooth
development, no information is available for dental epithelial
stem cells in humans. This niche may be specific to rodents
Table 1
Characteristics of human dental tissue and gingiva-derived MSCs.
Stem cells
(Ref.)
CD antigen expression Other representative
markers
PD In vitro differentiation
capacity
In vivo tissue
formation capacity
Positive Negative
DPSCs
[71,73,74,85,
184–186]
CD9, CD10, CD13, CD29,
CD44, CD49d, CD59, CD73,
CD90, CD105, CD106, CD146,
CD166
CD14, CD31,
CD34, CD45,
CD117, CD133
STRO-1, Nestin >120 dent (od), mes (os, ad,
cho, myo), ect (neu)
dent (dentin, pulp),
mes (adipose,
muscle)
SHED
[73,187–190]
CD13, CD44, CD73, CD90,
CD105, CD146
CD14, CD19,
CD34, CD43,
CD45
STRO-1, Oct-4,
Nanog, Nestin,
SSEA-3, SSEA-4
>140 dent (od), mes (os, ad,
cho, myo, endo), ect
(neu)
dent (dentin),
mes (bone,
microvessel)
PDLSCs
[76,184,191,192]
CD9, CD10, CD13, CD29, CD44,
CD49d, CD59, CD73, CD90,
CD105 CD106, CD146, CD166
CD31, CD34,
CD45
STRO-1, Scleraxis ND dent (cem), mes (os, ad,
cho), ect (neu)
dent (cementum,
PDL), mes
(alveolar bone)
DFSCs
[184,193–195]
CD9, CD10, CD13, CD29, CD44,
CD49d, CD59, CD73, CD90,
CD105, CD106, CD166
CD31, CD34,
CD45, CD133
STRO-1, HLA
class 1
ND dent (cem), mes (os, ad,
cho), ect (neu)
dent (cementum,
PDL), mes
(alveolar bone)
TGPC
[83,196,197]
CD29, CD44, CD73, CD90,
CD105, CD106, CD166
CD14, CD34,
CD45
STRO-1, Oct-4,
Nanog, HLA
class 1
ND mes (os, ad, endo),
ect (neu), end (hep)
mes (bone)
SCAP
[85,86,198]
CD49d, CD51/61, CD56, CD73,
CD90, CD105, CD106, CD146,
CD166
CD14, CD18,
CD34, CD45,
CD117, CD150
STRO-1, Nestin,
Survivin
>70 mes (ad), ect (neu) dent (dentin,
pulp)
GMSCs (OMSCs)
[98,100,199,200]
CD29, CD44, CD73, CD90, CD105,
CD106, CD146, CD166
CD34, CD45,
CD117
STRO-1, Oct-4,
Nanog, Nestin,
SSEA-4, HLA-ABC,
Sox-2, Tra2-49, Tra2-54
>20 mes (os, ad, cho),
ect (neu, glia cell), end
(definitive endoderm cell)
mes (bone,
cartilage, fat,
muscle), ect
(epithelia, neural tissue)
PD: population doubling; ND: not determined; PDL: periodontal ligament; differentiation lineages: dent (dentinogenic lineage), mes (mesodermal lineage), ect
(ectodermal lineage), end (endodermal lineage), od (odontoblast), os (osteoblast), ad (adipocyte), cho (chondrocyte), myo (myoblast), neu (neuronal cell), endo
(endothelial cell), cem (cementoblast), hep (hepatocyte).
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erupt continuously throughout the life of the animal.
Mesenchymal progenitor or stem cells have also long been
assumed to exist in dental tissues [60–62] because some dental
tissues, such as periodontal tissues and dental pulp, can
regenerate or form reparative dentin by a natural process if the
environmental conditions are suitable after dental treatments
[61–69]. To date, several MSC sources have been identified in
dental tissues, and the isolated stem cells [70] have been
extensively characterized (Table 1).
In 2000, adult human dental stem cells were first identified in
the dental pulp (dental pulp stem cells; DPSCs: Fig. 4A) [71], and
these cells had phenotypic characteristics similar to those of
BMSCs [72]. MSC-like cells were subsequently also isolated from
the dental pulp of human deciduous teeth (stem cells from human
exfoliated deciduous teeth; SHED) [73]. DPSCs and SHED
possess definitive stem cell properties, such as multi-differentia-
tion and self-renewal [71,73,74]. Importantly, these cells have the
specific ability to regenerate the dentin–pulp complex when
transplanted into immunocompromised mice. In addition, SHED
can specifically induce the formation of a bone-like matrix with a
lamellar structure by recruiting host cells [73,75]. This distinct
property of SHED for bone formation may be explained by the
nature of deciduous teeth, whose root resorption is accompanied
by new bone formation surrounding the root.
The periodontal ligament is another adult MSC source in
dental tissues, and periodontal ligament stem cells (PDLSCs)
can even be isolated from extracted teeth. PDLSCs have
demonstrated the ability to regenerate periodontal tissues(cementum, periodontal ligament and alveolar bone) in
experimental animal models [76,77]. A recent report suggested
that the characteristics of the PDLSCs may depend on the
harvest location because PDLSCs from the alveolar bone
surface displayed superior alveolar bone regeneration com-
pared with PDLSCs from the root surface [78].
MSC-like cells have also been identified in the ‘‘developing’’
dental tissues, such as the dental follicle, dental mesenchyme and
apical papilla. The dental follicle (Fig. 4B), which is a dental sac
that contains the developing tooth and differentiates into the
periodontal ligament, contains dental follicle stem cells (DFSCs)
with the ability to regenerate periodontal tissues [79–82]. Ikeda
et al. [83] identified distinctive stem cells in the dental
mesenchyme of the third molar tooth germ at the late bell stage
(tooth germ progenitor cells: TGPCs) with high proliferation
activity and the capability to differentiate in vitro into lineages of
the three germ layers including osteoblasts, neural cells and
hepatocytes. Stem cells from the apical papilla (SCAP) [84–86]
were found in the papilla tissue in the apical part of the roots of
developing teeth (Fig. 4C). Compared with DPSCs, SCAP
demonstrate better proliferation in vitro and better regeneration
of the dentin matrix when transplanted in immunocompromised
mice. These findings suggest that ‘‘developing’’ dental tissues
may provide a better source for immature stem cells than
‘‘developed’’ dental tissues.
It should be noted that these tissues are often discarded in the
clinic as medical waste and therefore present a particularly
attractive source for stem cells because of their availability.
Many research groups have therefore used dental stem cells to
Fig. 4. Sources of adult stem cells in dental tissues. (A) After a tooth was cut horizontally, the pulp tissue (arrow) in the pulp chamber was exposed; this pulp provides
dental pulp stem cells (DPSCs). (B) Extracted impacted third molar (10-year-old female) containing the dental follicle (dotted line) that provides dental follicle stem
cells (DFSCs). Bar: 5 mm. (C) Extracted impacted third molar (18-year-old male) containing root apical papillae (asterisks) that are a source of stem cells from the
apical papilla (SCAP). Bars: 5 mm.
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potential clinical applications [85,87–91]. However, these cells
are heterogeneous with various differentiation states, as they
include true ‘‘stem’’ cells, progenitor cells and possibly
fibroblasts [71,73,74,76,85,86]. Therefore, it is necessary to
effectively classify and purify these cells to prevent unexpected
clinical results.
2.1.4. Oral mucosa-derived stem cells
The oral mucosa is composed of stratified squamous
epithelium and underlying connective tissue consisting of
the lamina propria, which is a zone of well-vascularized tissue,
and the submucosa, which may contain minor salivary glands,
adipose tissue, neurovascular bundles and lymphatic tissues
depending on the site [92]. To date, two different types of
human adult stem cells have been identified in the oral mucosa.
One is the oral epithelial progenitor/stem cells, which are a
subpopulation of small oral keratinocytes (smaller than 40 mm)
[93]. Although these cells seem to be unipotential stem cells,
i.e., they can only develop into epithelial cells, they possess
clonogenicity and the ability to regenerate a highly stratified
and well-organized oral mucosal graft ex vivo [94,95], which
suggests that they may be useful for intra-oral grafting [96].
Other stem cells in the oral mucosa have been identified in
the lamina propria of the gingiva, which attaches directly to the
periosteum of the underlying bone with no intervening
submucosa (see the inset of Fig. 2) [97]. The gingiva overlying
the alveolar ridges and retromolar region is frequently resected
during general dental treatments and can often be obtained as a
discarded biological sample. In 2009, Zhang et al. [98] first
characterized human gingiva-derived MSCs (GMSCs), which
exhibited clonogenicity, self-renewal and a multipotent
differentiation capacity similar to that of BMSCs. GMSCs
proliferate faster than BMSCs, display a stable morphology and
do not lose their MSC characteristics with extended passaging
[99]. Recently, Marynka-Kalmani et al. [100] reported that a
multipotent neural crest stem cell-like population, termed oral
mucosa stem cells (OMSCs), can be reproducibly generated
from the lamina propria of the adult human gingiva and can
differentiate in vitro into lineages of the three germ layers. Theinherent stemness of gingival cells may therefore partly explain
the high reprogramming efficiency of gingiva-derived fibro-
blastic cell populations during iPS cell generation [101]. The
multipotency of GMSCs/OMSCs and their ease of isolation,
clinical abundance and rapid ex vivo expansion provide a great
advantage as a stem cell source for potential clinical
applications.
2.1.5. Periosteum-derived stem/progenitor cells
The periosteum is a specialized connective tissue that covers
the outer surface of bone tissue. The osteogenic capacity of the
periosteum of long bones was reported in 1932 [102], and the
periosteum membrane was found to form a mineralized
extracellular matrix under the appropriate in vitro conditions.
Several subsequent studies have addressed other aspects of
periosteal osteogenesis, including long bone development and
the periosteum [103], the relationship between the vasculature
and the periosteum [104] and the periosteal osteogenic capacity
[105].
Histologically, the periosteum is composed of two distinct
layers and up to five distinctly different functional regions when
it is dissociated enzymatically and cultured [106]. The outer
area contains mainly fibroblasts and elastic fibers, and the inner
area contains MSCs [107–109], osteogenic progenitor cells
[110,111], osteoblasts and fibroblasts, as well as microvessels
and sympathetic nerves. Although the heterogeneous cell
population isolated from the periosteum seems to preferentially
undergo osteogenic differentiation [110,111], these cells are
capable of differentiating into osteoblasts, adipocytes and
chondrocytes and expressing the typical MSC markers
[107,109]. In addition, De Bari et al. [108] demonstrated that
single-cell-derived clonal populations of adult human perios-
teal cells possess mesenchymal multipotency, as they
differentiate to osteoblast, chondrocyte, adipocyte and skeletal
myocyte lineages in vitro and in vivo. Therefore expanded
periosteum-derived cells could be useful for functional tissue
engineering, especially for bone regeneration.
A comparative analysis of canine MSCs/progenitor cells
showed that the in vivo potential of periosteum cells to form
bone was higher than that of ilium-derived BMSCs and alveolar
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mandibular periosteum cells were comparable to those of
maxillary tuberosity-derived BMSCs, and both cell populations
formed ectopic bone after subcutaneous implantation in mice
[113]. Agata et al. [114] reported that human periosteal cells
proliferated faster than marrow stromal cells, and subcutaneous
transplants of periosteal cells treated with a combination of
recombinant growth factors formed more new bone than
BMSCs in mice. Periosteal grafts have been shown to induce
cortical bone formation, whereas bone marrow grafting induced
cancellous bone formation with a bone marrow-like structure in
a rat calvarial defect model [115], which implies that the source
of the transplanted cells can influence the structural properties
of the regenerated bone.
The robust osteogenic potential of periosteum-derived
cells has inspired dentists to use the periosteum for orofacial
bone regeneration. Indeed, the inverted periosteal flap
technique [116] has been recommended for alveolar bone
augmentation in conjunction with implant placement or in
combination with bone graft surgery. Additionally, cultured
periosteum-derived cells have been used for alveolar ridge or
maxillary sinus floor augmentation in clinical research that
successfully demonstrated enhanced bone remodeling and
lamellar bone formation with subsequent reliable implant
insertion [117] and reduced postoperative waiting time after
implant placement [118]. Therefore, the periosteum is a
source of stem/progenitor cells for bone regeneration,
particularly for large defects.
2.1.6. Salivary gland-derived stem cells
Patients afflicted with head and neck cancer who receive
radiotherapy suffer from an irreversible impairment of salivary
gland function that results in xerostomia and a compromised
quality of life. Therefore, stem cells in the adult salivary gland
are expected to be useful for autologous transplantation therapy
in the context of tissue engineered-salivary glands or direct cell
therapy. The salivary glands originate from the endoderm and
consist of acinar and ductal epithelial cells with exocrine
function. After ligation of the salivary gland duct, the acinar
cells undergo apoptosis, and the duct epithelium subsequently
proliferates. Although the existence of salivary gland stem cells
has been suggested by in vivo studies [119,120], a single stem
cell that gives rise to all epithelial cell types within the gland
has not yet been identified. Thus far, the isolation of stem cells
in the salivary glands has been attempted through the cell
culture of dissociated tissue. Kishi et al. [121] isolated salivary
gland stem/progenitor cells from rat submandibular glands and
found that the cells are highly proliferative and express acinar,
ductal and myoepithelial cell lineage markers. Lombaert et al.
[122] reported that an in vitro floating sphere culture method
could be used to isolate a specific population of cells expressing
stem cell markers from dissociated mouse submandibular
glands. These cell populations could differentiate into salivary
gland duct cells as well as mucin- and amylase-producing
acinar cells in vitro. Progenitor/stem cells were also isolated
from swine [123] and human [122,124] salivary glands. In
addition, the intra-glandular transplantation of cells isolatedfrom mouse submandibular glands successfully rescued the
salivary function of irradiated salivary glands [122,125], and
Neumann et al. [126] reported the long-term cryopreservation
of integrin-a6b1 expressing cells as a sub-population of rat
salivary gland progenitor cells. These reports suggest that the
salivary gland is a promising stem cell source for future
therapies targeting irradiated head and neck cancer patients.
However, primary cultures of dispersed cells will always
contain a number of cells with different origins, such as
parenchymal cells, stromal cells and blood vessel cells, which
makes it difficult to select salivary gland stem cells. Indeed,
Gorjup et al. [127] isolated primitive MSC-like cells from the
human salivary gland, but possibly from stromal tissue, which
expressed embryonic and adult stem cell markers and could be
guided to differentiate into adipogenic, osteogenic and
chondrogenic cells. To obtain a genuine stem cell population
that can be considered to be a true stem cell for the salivary
gland, it is necessary to select cells carrying a specific marker or
labeled with induced reporter proteins [128].
2.1.7. Adipose tissue-derived stem cells (ASCs)
Adipose tissue is an abundant source of MSCs and has been
extensively studied in the field of regenerative medicine as a
stem cell source. Adipose-derived MSCs can be readily
harvested via lipectomy or from lipoaspirate from areas such
as the chin, upper arms, abdomen, hips, buttocks and thighs in
large numbers with low donor-site morbidity [129], as
liposuction is one of the most common cosmetic procedures.
Although the intrinsic characteristics of ASCs appear to be
different from those of BMSCs [26,130–132], ASCs exhibit
robust osteogenesis and are thus expected to be an alternative
source of MSCs for bone regeneration in dentistry. Indeed, the
feasibility of using autologous ASCs for orofacial bone
regeneration and implant placement has been demonstrated
[133,134]. Pieri et al. [135] demonstrated that the transplanta-
tion of autologous ASCs with an inorganic bovine bone scaffold
(Bio-Oss1) enhanced new bone formation and implant
osseointegration following vertical bone augmentation of the
calvarial bone of rabbits, which suggests that ASCs may be
useful for vertical alveolar bone augmentation for implant
treatment.
Periodontal tissue regeneration using ASCs has also been
successfully demonstrated in a rat experimental animal model
[136], and an in vitro study showed that rat ASCs acquired
cement blast features when cultured in dental follicle cell
conditioned medium containing dentin non-collagenous
proteins [137]. In addition, Ishizaka et al. [138] demonstrated
that ASC transplantation induced pulp regeneration in the
root canal after pulpectomy in dogs, and Hung et al. [139]
demonstrated that ASCs implants were able to grow self-
assembled new teeth containing dentin, periodontal ligament
and alveolar bone in adult rabbit extraction  sockets with a
high success rate. Further studies on the isolation, character-
ization and application of ASCs to enhance their efficacy for
bone and periodontal regeneration will provide a definitive
protocol for the use of waste fat tissues in future clinical
applications.
Fig. 5. iPS cell generation from human gingiva. (A) The patient’s gingiva was resected during dental implant surgery (inset: resected gingiva). (B) Plastic-adherent
fibroblasts isolated from the gingiva (bar: 60 mm). (C) iPS cells generated from the gingival fibroblasts by retroviral transduction of the reprogramming factors (bar:
500 mm). The figure was reproduced under the open-access license policies of PLoS One [101].
H. Egusa et al. / Journal of Prosthodontic Research 56 (2012) 151–1651582.2. Pluripotent stem cells
Pluripotency is defined as the capacity of individual cells to
generate all lineages of the mature organism in response to
signals from the embryo or cell culture environment [140].
Because of their intrinsic pluripotency and unlimited self-
renewal, dental applications of pluripotent stem cells are
expected to primarily involve basic research on developmental
biology, drug testing and regenerative therapies. Therefore, the
differentiation of pluripotent cells towards clinically useful oral
lineages is primary focus in dental research.
2.2.1. ES cells
ES cells are produced by culturing cells collected from the
undifferentiated inner cell mass of the blastocyst, which
represents an early stage of embryonic development after
fertilization [141,142]. This embryonic origin is the major
reason that ethical and moral questions are associated with the
use of human ES cells [143]. Nonetheless, ES cells are of great
interest to scientists and clinicians because of their develop-
mental capacity to differentiate in vitro into cells of all somatic
cell lineages as well as into male and female germ cells [143].
In the field of dentistry, ES cells are expected to provide an in
vitro model system and transplantation substrate for animal
models to study the controlled differentiation of pluripotent
stem cells into specific lineages of oral tissues and organs, such
as mucosa [144], alveolar bone [145], periodontal tissues [146]
and teeth [147]. These approaches can be useful to obtain a
better understanding of oral developmental biology and may
lead to future strategies in regenerative dentistry that meet
clinical needs. However, in addition to the ethical issues, the
tissue engineering applications of ES cells are limited because
the cells are allogenic and thus may be immunologically
incompatible between donors and recipients. To overcome this
issue, the creation of human ES cell banks with human
leukocyte antigen (HLA) matching and the generation of
customized, patient-specific ES cells via nuclear transplanta-
tion from the patient’s own cells have been proposed to enable
combined gene and cell therapy [143]. However, these
strategies rely on inefficient and expensive techniques and
are tedious and ethically cumbersome, especially for dentists,
unless a cooperative team can be organized with experts who
routinely deal with patients’ embryos.2.2.2. iPS cells
In 2006, Dr. Shinya Yamanaka discovered that normal
mouse adult skin fibroblasts can be reprogrammed to an
embryonic state by introducing four genetic factors (Oct3/4,
Sox2, Klf4 and c-Myc), and the resulting cells were termed iPS
cells [23]. Just a year after the mouse study was reported, the
findings were replicated in human skin cells [24,148], which
opened the door to generate a patient-specific ES cell equivalent
from autologous somatic cells. This technology is expected to
revolutionize medicine because of the capacity of iPS cells to
develop into all tissues/organs and thereby support the
emerging field of ‘‘personalized medicine’’, which uses a
patient’s own cells to provide biologically compatible therapies
and individually tailored treatments.
For dental applications, iPS cells that can be efficiently
generated from tissues that are easily accessed by dentists have
great potential, and iPS cells have been generated from various
oral mesenchymal cells, such as SCAP [149], DPSCs and
SHED [149,150], TGPCs [151], buccal mucosa fibroblasts
[152], gingival fibroblasts (Fig. 5) [101,153] and periodontal
ligament fibroblasts [153]. Most of these cells have a higher
reprogramming efficiency than the conventionally used skin
fibroblasts (Table 2), possibly because of their high expression
of endogenous reprogramming factors and/or ES cell-asso-
ciated genes [150] as well as their high proliferation rate [101].
Therefore, cells of oral origin are expected to provide an ideal
iPS cell source, especially for dentists and dental researchers.
These iPS cells may be of particular importance for
developing innovative technologies to regenerate missing jaw
bones, periodontal tissues, salivary glands and lost teeth [9]. In
a mouse model, iPS cells combined with enamel matrix
derivatives provided greatly enhanced periodontal regeneration
by promoting the formation of cementum, alveolar bone and
periodontal ligament [154]. Recent in vitro studies demon-
strated the differentiation of mouse iPS cells into ameloblasts
[155] and odontogenic mesenchymal cells [156], which may be
useful approach for tooth bioengineering strategies.
However, the scientific understanding of iPS cells and how
to control their differentiate fate is still limited. Despite the
similarities between iPS cells and ES cells, it remains unclear
whether these pluripotent stem cells are exactly equal. Recent
studies have indicated that not all iPS cells are equal and that
iPS cells retain an epigenetic memory of their former
Table 2
The reprogramming efficiency of human somatic cells from different tissues.
Authors (Ref.) iPS cell source Reprogramming method Efficiency Time
Takahashi et al. [24] Skin fibroblasts O/S/K/M (RV) 0.02% 25–30 days
Aasen et al. [164] Foreskin keratinocytes O/S/K/M (RV) 1% 14–21 days
Foreskin fibroblasts O/S/K/M (RV) <0.01% 31 days
Sun et al. [201] ASCs O/S/K/M (LV) <0.2% 16 days
Yan et al. [149] SHED O/S/N/L (LV) <0.08% 21 days
SCAP O/S/N/L (LV) 0.07% 21 days
DPSCs O/S/K/M (RV) 0.1% 21 days
Tamaoki et al. [150] DPSCs O/S/K (RV) <0.06% 30 days
O/S/K/M (RV) <0.24% 21 days
Oda et al. [151] TGPCs O/S/K (RV) <0.03% 30 days
Clonally expanded TGPCs O/S/K (RV) <0.2% 30 days
Miyoshi et al. [152] Buccal mucosa fibroblasts O/S/K/M (RV) 0.02% 13–25 days
Wada et al. [153] Gingival fibroblasts O/S/K/M (RV) – 28–30 days
Periodontal ligament fibroblasts O/S/K/M (RV) – 28–30 days
Reprogramming factors (O: Oct3/4, S: Sox2, K: Klf4, M: c-Myc, N: Nanog, L: Lin28) and viral vectors (RV: retrovirus; LV: lentivirus; SV: sendai virus). ASCs:
adipose tissue-derived stem cells, SHED: stem cells from human exfoliated deciduous teeth, SCAP: stem cells from the apical papilla, DPSCs: dental pulp stem cells,
TGPCs: tooth germ progenitor cells.
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[157,158]. Therefore, strategies that bypass the epigenetic
memory to create more ES-like iPS cells or that can identify iPS
cell sources that are amenable to efficient guided differentiation
to the target lineage may be necessary. To achieve this goal, the
generation of more stringent markers of pluripotency and
assays to determine the abilities of a given iPS cell line is
critical [159].
In addition, the prevention of tumor formation upon in vivo
implantation of iPS cells is critical for their clinical application.
The original protocol to generate iPS cells [160] uses the c-Myc
oncogene as one of the reprogramming factors and a retroviral
vector for gene transfer, which raises concern about possible
carcinogenic properties. Recent rapid progress in iPS cell
research has virtually resolved these problems, e.g., by using L-
Myc as a replacement for c-Myc [161] or via the application of
small molecules rather than viral gene delivery [162,163], the
generation of reprogramming protocols to enhance the
reprogramming efficiency without requiring c-Myc [164]
and the use of non-viral components such as protein [165],
microRNA [166], synthetic mRNA [167] or episomal plasmids
[168] for reprogramming. However, serious clinical problems
can still arise when residual undifferentiated iPS cells
remaining among the differentiated target cells uncontrollably
proliferate to form teratomas in the transplanted site. To address
this critical issue, several approaches are being investigated,
such as a selective ablation method to remove teratomas via
suicide genes and chemotherapy [169,170], as well as a cell
sorting method to remove teratoma-forming cells using specific
antibodies [171].
3. Suitable stem cells for regenerative dentistry
Stem cells suitable for regenerative medicine/dentistry must
be subject to the complete control of cell fate in the body toensure the safety of the patient. In this regard, only adult MSCs
currently have realistic clinical potential. Indeed, the regenera-
tion of bone and periodontal tissues by MSCs has been
extensively evaluated, with some studies already reaching the
clinic (see Part II of this review). Suitable stem cells for dental
tissue engineering should also be able to differentiate into the
target tissue/organ and should be easily collected and prepared,
and possible immunomodulatory properties can be used to
provide a further benefit.
3.1. Differentiation capacity
As described in the previous chapters, BMSCs, particularly
those from the orofacial bone marrow, and periosteum-derived
stem/progenitor cells may be suitable for alveolar bone
regeneration because of the compatibility of the cell source
with the target tissue. Similarly, dental tissue-derived MSCs
may be appropriate for the regeneration of dental mesenchyme-
derived tissues, such as dentin, pulp and periodontal tissues (see
Section 2.1.3). However, the differentiation capacity of adult
MSCs is principally limited to mesenchymal lineages, which
hinders their application to the regeneration of complex oral
organs, such as teeth and salivary glands, which are formed
during development by the interaction of epithelial and
mesenchymal tissues. One strategy for achieving organ
regeneration has focused on identifying organ-specific stem
cells based on the capacity of a single tissue-specific stem cell
to form the epithelial components of mammary glands [172] or
gastric units [173]. However, a single postnatal stem cell with
organogenic capacity has not yet been identified in the teeth or
salivary glands.
From this point of view, pluripotent stem cells are promising
for the regeneration of complex organs. For example, the three-
dimensional culture of mouse ES cell aggregates resulted in the
efficient self-formation of the optic cup, which is a structural
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adenohypophysis tissues [175], which suggests that ES cells
have the capacity for balanced organogenesis. However, ES
cells are unlikely to be appropriate for cell therapies because of
the associated issues of immune rejection and medical ethics
(see Section 2.2.1). Alternatively, autologous patient-derived
iPS cells may be able to overcome these issues, although
formidable technical challenges must be surmounted to make
iPS cell-based therapies a reality in dentistry (see Section
2.2.2). In addition, the successful implementation of iPS cell
therapy will require an understanding of how to induce these
cells to form specific progenitor cells for the tissues and organs
targeted for regeneration. In this scenario, studies on the
developmental mechanisms of oral tissues and organs using
tissue/organ-specific stem cells will also be necessary for the
further development of iPS cell technology.
3.2. Accessibility
With regard to accessibility, bone marrow aspiration from
the iliac crest and liposuction from extra-oral tissue is not an
easy operation for dentists because of the limitations of the
dental license and the dental specialization. In contrast,
orofacial bone marrow, periosteum, salivary glands and dental
tissues are accessible stem cell sources for dentists; however,
the isolation of stem cells from these locations may still not be
convenient because it requires surgical procedures or tooth or
pulp extraction. Additionally, even if impacted wisdom teeth
could be a cell source, not all adults require the extraction of the
wisdom teeth. Furthermore, these adult stem cells are present in
small quantities and can therefore be difficult to isolate, purify
and expand homogeneously. In contrast, the gingiva, which is a
tissue that is easily obtainable by dentists and whose cells can
be easily expanded from patients with minimal discomfort,
seems to be a promising source of adult stem cells [98–100] and
iPS cells [101] in dentistry (see Sections 2.1.4 and 2.2.2). More
studies are necessary to determine the regenerative abilities of
gingiva-derived stem cells in oral tissues.
Research on all available stem cells in dentistry should be
continued to permit their manipulation for the regeneration of
oral tissues. Based on the accumulated knowledge, the type of
stem cell to be used for a given application will be decided by
considering a balance of the differentiation capacity with
accessibility/availability, which may vary on a case-by-case
basis.
3.3. Immunomodulation
In addition to tissue repair and regeneration, immunomo-
dulatory properties have also recently been identified for MSCs
in animals and humans that may be related to therapeutic effects
such as angiogenesis, anti-inflammation and antiapoptosis
[176]. Furthermore, recent reports suggest that MSCs have low
inherent immunogenicity [177]. Therefore, the immunomodu-
laory properties of MSCs may make them more attractive than
other types of stem cells for some applications in cell
transplantation.Previous reports demonstrated that human oral tissue-
derived MSCs, such as DPSCs [178], SHED [179], PDLSCs
[180], SCAP [181] and GMSCs [98], have immunomodulatory
properties similar to those of BMSCs. In addition, systemically
injected GMSCs have been shown to home to the wound site
and promote wound repair [182], and oral mucosal progenitor
cells appear to have a more fetal phenotype for immune
recognition, with immunomodulation that occurs under a
mechanism different from that of BMSCs [183]. Therefore, the
gingiva is currently a promising stem cell source that may have
wide-ranging potential for future immune-related therapies in
addition to regenerative medicine.
4. Conclusions
Growing evidence has demonstrated that the oral and
maxillofacial region is a rich source of adult stem cells. Many
intra-oral tissues, such as deciduous teeth, wisdom teeth and the
gingiva, are not only easily accessible from the oral cavity but
can also often be obtained as a discarded biological sample.
Therefore, dental professionals should recognize the promise of
the emerging field of regenerative dentistry and the possibility
of obtaining stem cells during conventional dental treatments
that can be banked for autologous therapeutic use in the future.
The discarded oral tissues can also be used to generate iPS cells
that can be used not only for the autologous cell-based
regeneration of complex oral tissues but also for the patient-
specific modeling of oral diseases and the development of
tailor-made diagnostic and drug screening tools for alveolar
bone augmentation and oral cancer treatment.
Further studies are necessary to establish evidence-based
practices to educate dentists and patients regarding the use of
stem cells in autologous regenerative therapies. Studies on the
relatively well-characterized stem cells, such as BMSCs and
other adult MSCs, should be continued to identify factors
responsible for the successful outcome of stem cell-based bone/
periodontal tissue regeneration. The immunomodulatory
properties of stem cells under consideration for applications
in dentistry should be investigated to facilitate the grafting of
the transplanted cells at inflamed sites. Studies on ES/iPS cells
may reveal the complex developmental process of oral organs,
such as the teeth and salivary glands. Research efforts on adult
stem cells and pluripotent stem cells should be concomitantly
performed with cross-communication to permit the develop-
ment of new and effective strategies for regenerative dentistry.
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